Related Experiment Video
Updated: Jul 15, 2026
11:37
Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting
Published on: June 18, 2018
Concentration of bone marrow mononuclear cells using a programmable blood cell separator
A R Orlina1, J C Conant, P J DeChristopher
1Division of Transfusion Medicine, Michael Reese Hospital & Medical Center, Chicago.
Journal of Clinical Apheresis
|January 1, 1991
Summary
A modified plateletpheresis procedure (M-PRO-1) for bone marrow processing yielded higher purity of mononuclear cells (MNCs) with less red blood cell (RBC) contamination compared to the standard lymphocytapheresis procedure (PRO-3). Both methods achieved similar hematopoietic recovery in patients undergoing myelo-ablative chemotherapy.
Area of Science:
- Hematology
- Transplant Medicine
- Cellular Therapy
Background:
- Autologous bone marrow rescue is a critical component of myelo-ablative chemotherapy for solid tumors.
- Efficient processing of bone marrow to isolate mononuclear cells (MNCs) is essential for successful transplantation.
- Standard procedures for bone marrow processing may have limitations in cell purity and processing time.
Purpose of the Study:
- To compare the efficacy of a modified plateletpheresis procedure (M-PRO-1) against a standard lymphocytapheresis procedure (PRO-3) for bone marrow processing.
- To evaluate MNC recovery, purity, and red blood cell (RBC) contamination between the two procedures.
- To assess the impact of different processing methods on hematopoietic recovery and personnel time.
Main Methods:
- Bone marrow samples from adult cancer patients were processed using either standard Procedure 3 (PRO-3) or a modified Procedure 1 (M-PRO-1).
- MNC recovery, concentrate volume, MNC percentage of white blood cells (WBC), and residual RBC volume were quantified for both procedures.
- Hematopoietic recovery was defined by post-transplant granulocyte and platelet counts, and personnel time was recorded.
Main Results:
- M-PRO-1 processing resulted in a higher percentage of MNCs (94% +/- 7%) in the concentrate with significantly less RBC contamination (7 ml +/- 3 ml) compared to PRO-3 (59% +/- 27% MNCs, 49 ml +/- 47 ml RBCs).
- MNC recovery rates were similar between the two groups (PRO-3: 68% +/- 22%; M-PRO-1: 63% +/- 22%).
- Hematopoietic recovery was comparable for both groups, and M-PRO-1 demonstrated reduced personnel time due to automation.
Conclusions:
- The modified Procedure 1 (M-PRO-1) for plateletpheresis is superior to the standard Procedure 3 (PRO-3) for bone marrow processing due to superior MNC purity and reduced RBC contamination.
- Both procedures support comparable hematopoietic recovery, but M-PRO-1 offers advantages in cell product quality and processing efficiency.
- M-PRO-1 represents an improved method for preparing bone marrow for autologous rescue in patients undergoing myelo-ablative chemotherapy.
